1. Academic Validation
  2. Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140

Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140

  • ACS Med Chem Lett. 2010 Dec 2;2(2):124-9. doi: 10.1021/ml1002508.
Chris P Miller 1 Maysoun Shomali 1 C Richard Lyttle 1 Louis St L O'Dea 1 Hillary Herendeen 1 Kyla Gallacher 1 Dottie Paquin 1 Dennis R Compton 2 Bishwabhusan Sahoo 2 Sean A Kerrigan 2 Matthew S Burge 2 Michael Nickels 2 Jennifer L Green 2 John A Katzenellenbogen 3 Alexei Tchesnokov 4 Gary Hattersley 1
Affiliations

Affiliations

  • 1 Radius Health, Inc., 300 Technology Square, Cambridge, Massachusetts 02139, United States.
  • 2 Obiter Research, 2809 Gemini Court, Champaign, Illinois 61822-9647, United States.
  • 3 Department of Chemistry, University of Illinois at Urbana-Champaign, 600 South Mathews Avenue, Urbana, Illinois 61801, United States.
  • 4 Cambridge Major Laboratories, Inc., W130 N10497 Washington Drive, Germantown, Wisconsin 53022, United States.
Abstract

This report describes the discovery of RAD140, a potent, orally bioavailable, nonsteroidal selective Androgen Receptor modulator (SARM). The characterization of RAD140 in several preclinical models of anabolic androgen action is also described.

Keywords

Androgen; Herschberger assay; SARM; cachexia; oxadiazole; primate.

Figures
Products